Science

Science, technology and the emergence of AI have converged to make precision medicine for acute care a reality. This is how we deliver healthcare tailored to biology.

Research & Development

NOSIS™

Partners

Evidence

The Sepsis ImmunoScore® Predicts Sepsis, Mortality, and Deterioration Better than Clinical Scores and Widely Available Biomarkers

Read More →

Platform

Prenosis is developing a pipeline of integrated diagnostics and therapeutics grounded in each patient's unique biological profile, using deep data science and AI to give clinicians tools that reflect the true complexity of critical disease.

Sepsis ImmunoScore®

Clinical Trials

Pipeline

BioAegis Therapeutics Announces Collaboration with Prenosis to Advance AI-Driven Precision Medicine in Inflammatory Disease

Read More →

Resources

Blogs, articles, videos, and podcasts exploring how precision medicine and AI are changing the way clinicians detect and treat critical conditions.

Newsroom

Resource Library

Events

Why We Call It an “AI-Biomarker”

Read More →

Newsroom

Read the latest Prenosis peer-reviewed articles and items from scholarly journals.

Newsroom

Sepsis ImmunoScore Outperforms Conventional Sepsis Tools

Read More →

About

As a biology-based technology company, we combine data science with AI to transform how critical conditions are diagnosed and treated.

Mission, Vision & Values

Careers

Leadership

Investors

Awards

Prenosis and Winners of the Chicago Innovation Awards Ring the Opening Nasdaq Bell

Read More →

Biomarker-based Clustering to Identify Distinct Host Response Signatures in Hospitalized Patients With Suspected Infection

Originally published May 2025 in American Journal of Respiratory and Critical Care Medicine

ABSTRACT | Hospitalized patients with suspected infection experience highly heterogeneous complications and outcomes, including sepsis and death. Differences in host responses across these patients are poorly understood. Thus, we sought to determine the breadth of biomarker signatures and identify distinct molecular phenotypes to better elucidate this population’s heterogeneity.

Read the full abstract, co-authored by Prenosis staff: Carlos Lopez-Espina, Greg Watson, Akhil Bhargava, Lee Schmalz, Shah Khan, and Bobby Reddy, Jr.